Harrow Expands Patient-First Access With Launch of “Harrow Access for All”
Harrow announced the debut of Harrow Access for All (HAFA), a nationwide program designed to make it easier and more affordable for patients to obtain the company’s full range of branded, generic, and compounded eye-care medications.
The new HAFA platform is an evolution of the Vevye Access for All (VAFA) initiative introduced in March 2025. VAFA was created to reduce cost and administrative barriers for Vevye(cyclosporine ophthalmic solution) 0.1%, a prescription treatment for the signs and symptoms of dry eye disease. According to Harrow, VAFA’s streamlined, patient-first model resonated quickly with prescribers and patients with prescriptions for Vevye growing 66% in the second quarter of 2025.
With HAFA, Harrow is extending this approach beyond a single product to its entire ophthalmic portfolio—including branded therapies, authorized generics (AGx), and compounded formulations. Beginning late 2025 and expanding into 2027, HAFA will serve as a single, unified access point for prescribers and patients.
According to Harrow, the platform provides:
Affordability: Transparent, predictable pricing across Harrow’s product lines
Streamlined Prescribing: Simplified ordering and reduced administrative overhead for physicians
Consistent Supply: A predictable path to treatment that supports better outcomes for patients
“As a company committed to reducing access barriers in the ophthalmic space, we recognize that affordability and ease of access are key components of being innovative," said Mark L. Baum, Chief Executive Officer of Harrow. "HAFA is designed to remove the financial and logistical obstacles that too often prevent patients from receiving timely access. Our goal is to ensure that every patient, regardless of insurance status or financial means, can access our sight-preserving medications without delay.”
Eligible commercially insured patients may pay as little as $0, with out-of-pocket costs for all eligible patients capped at $59, ensuring treatment affordability regardless of coverage status.
The HAFA program will be implemented in three phases:
- Phase 1 (Q4 2025 Launch Expected): Covers the majority of Harrow’s specialty product portfolio, including the upcoming launch of Byqlovi (clobetasol propionate ophthalmic suspension) 0.05%. Eligible patients will pay as little as $0 and no more than $59 out-of-pocket, significantly improving affordability while driving early adoption.
- Phase 2 (First Half of 2026 Launch Expected): Covers the majority of Harrow’s specialty product portfolio, and will include an expanded portfolio of AGx offerings, ensuring continued and improved patient access.
- Phase 3 (2027 Launch Expected): HAFA will ultimately extend across Harrow’s full portfolio of specialty, AGx, and compounded medicines. For eligible patients not covered by insurance, the program ensures uninterrupted access by offering an AGx or affordable cash-pay options, depending on the product, with compounded medication alternatives available as appropriate for the individual patients—guaranteeing that every patient can receive the medication they need.